Tiziana Life Sciences PLC Tiziana (NASDAQ: TLSA) Announces Phase II Foralumab’s Study Tiziana Life Sciences Plc (NASDAQ: TLSA) reported Tuesday that it is intending to commence Phase II study in Brazil for moderate-to-severe hospitalized COVID-19 sufferers to test Foralumab in a more adversely affected group of sufferers.
